Helping women with Parkinson's disease manage hormonal symptoms
Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers
This study is testing whether tracking menstrual cycles and symptoms with a mobile app can help women with Parkinson's disease better manage their hormonal symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 56 Years |
| Sex | Female |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 4 sites (Grenoble, Grenoble and 3 other locations) |
| Trial ID | NCT06582212 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to explore the relationship between the menstrual cycle and Parkinson's disease symptoms in pre-menopausal women. Participants will use the My Moves Matter mobile application to track their symptoms and hormonal changes over time. The study will assess the reliability of this app in capturing symptom fluctuations and compare subjective data from the app with objective clinical assessments. The goal is to improve management strategies for women experiencing hormonal-related worsening of Parkinson's symptoms.
Who should consider this trial
Good fit: Ideal candidates are pre-menopausal women aged 18-56 with a diagnosis of Parkinson's disease for at least two years.
Not a fit: Patients who are post-menopausal or have conditions that prevent them from completing study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide women with Parkinson's disease better tools to manage their symptoms related to hormonal changes.
How similar studies have performed: While there is ongoing research into tracking menstrual symptoms in women with Parkinson's disease, this specific approach using the My Moves Matter app is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-menopausal women * Diagnosis of PD according to the MDS criteria onset of PD symptoms since at least two years before inclusion * Age 18-56 years * On stable medication regimen for PD for at least two months without foreseen need to modify it within the next three months * With and without OCP or intrauterine devices (IUD Exclusion Criteria: * Post-menopausal women with PD * Any condition that, in the opinion of the investigator, will preclude the participant from successfully or safely completing study procedures (i.e., dementia, severe depression, etc.) * People not able to give an informed consent.
Where this trial is running
Grenoble, Grenoble and 3 other locations
- CHU Grenoble Alpes — Grenoble, Grenoble, France (Recruiting)
- CHU Nantes Hôpital Laennec — Nantes, France (Recruiting)
- CHU Rennes -Site Pontchaillou — Rennes, France (Recruiting)
- Chu Toulouse — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Elena MORO — CHU Grenoble Alpes
- Study coordinator: Elena MORO
- Email: emoro@chu-grenoble.fr
- Phone: 0476769452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.